Neogenomics Inc Stock Price, News & Analysis

NeoGenomics (NASDAQ:NEO) has announced the acquisition of Pathline, , a CLIA/CAP/NYS-certified laboratory in New Jersey. This strategic move strengthens NeoGenomics' presence in the Northeast U.S., a historically under-penetrated but growing market.

Founded in 2009, Pathline generates approximately 98% of its revenue from Northeast customers, offering comprehensive subspecialty pathology services including histopathology, immunohistochemistry, cytology, cytogenetics, flow cytometry, FISH, and molecular pathology.

The acquisition brings valuable New York State approvals and aims to enhance NeoGenomics' service capabilities in molecular and hematology-oncology testing. The integration is expected to generate substantial annual cost reductions and become accretive to AEBITDA starting in 2026.

NeoGenomics (NASDAQ:NEO), a leading oncology testing services company, has announced its participation in three major upcoming investor conferences in March:

- TD Cowen 45th Annual Health Care Conference in Boston, MA, featuring a fireside chat on March 4 at 1:50 p.m. ET

- Leerink Partners Global Healthcare Conference in Miami, FL, with a fireside chat scheduled for March 11 at 3:30 p.m. ET

- Barclays 27th Annual Global Healthcare Conference in Miami, FL, hosting a fireside chat on March 13 at 9:00 a.m. ET

All sessions will be available via live and archived webcasts through the Investor Relations section of NeoGenomics' website at ir.neogenomics.com.

NeoGenomics (NEO) reported its Q4 and full-year 2024 results, marking its ninth consecutive quarter of double-digit revenue growth. Full-year consolidated revenue increased 12% to $661 million, while Q4 revenue grew 11% to $172 million.

The company's full-year net loss decreased 11% to $79 million, while Q4 net loss increased 7% to $15 million. Full-year adjusted EBITDA showed significant improvement, increasing 1,036% to $40 million. Average revenue per clinical test increased by 5% to $465, driven by higher value tests and strategic reimbursement initiatives.

For 2025, NeoGenomics reaffirmed its guidance, projecting revenue between $735-745 million (11-13% growth) and adjusted EBITDA of $55-58 million (38-45% growth).

NeoGenomics (NASDAQ: NEO) announced it will release its fourth quarter and full year 2024 financial results before U.S. markets open on Tuesday, February 18, 2025. The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the results and recent highlights.

Investors can access the live webcast through the company's Investor Relations website at ir.neogenomics.com. For those joining by phone, the dial-in numbers are (888) 506-0062 (domestic) and (973) 528-0011 (international), with participant access code 167039. A replay of the webcast will be available shortly after the call.

NeoGenomics (NASDAQ:NEO) has announced its financial guidance for 2025 and updated its Long-Range Financial Plan. The company expects total revenues of $735-745 million and adjusted EBITDA of $55-58 million for 2025, representing year-over-year growth of 11-13% and 43-51% respectively from 2024 midpoint guidance.

The company's Long-Range Plan targets include annual revenue growth of 12-13% with NGS growth of ~25% per year, gross margin expansion of 100-150 basis points annually, and adjusted EBITDA improvement of 250-300 basis points per year. NeoGenomics aims to achieve positive cash flow from operations in 2025 and serve more than 1 million patients annually by 2028.

The company plans to retire its 2025 convertible notes maturing on May 1, 2025, using cash on hand.

NeoGenomics (NASDAQ:NEO) announced that CEO Chris Smith will retire effective April 1, 2025, with board member Tony Zook named as his successor. Under Smith's leadership since August 2022, the company achieved eight consecutive quarters of double-digit revenue growth and improved from negative $48 million Adjusted EBITDA in 2022 to an expected positive $37-40 million in 2024.

The company reaffirmed its 2024 financial guidance, projecting consolidated revenue between $655-667 million, net loss of $(81)-$(78) million, and Adjusted EBITDA of $37-40 million. During Smith's tenure, NeoGenomics served more than 1.5 million cancer patients and implemented a patient and customer-centric strategy.

Incoming CEO Tony Zook brings extensive healthcare experience, including his role as Executive Vice President of Global Commercial Operations at AstraZeneca, where he managed over $30 billion in revenues. Smith will remain as an advisor during the transition period.

NeoGenomics (NASDAQ: NEO), a leading oncology testing services company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. CEO Chris Smith will deliver a presentation with a Q&A session on Wednesday, January 15, at 1:30 p.m. PT/4:30 p.m. ET. The event will be accessible through a live webcast, with a replay available on the company's Investor Relations website at ir.neogenomics.com.

NeoGenomics (NASDAQ: NEO) published a study in ESMO Open demonstrating the effectiveness of circulating tumor DNA (ctDNA) in monitoring molecular residual disease (MRD) for high-risk melanoma patients. The research, conducted with Princess Margaret Hospital, analyzed 276 plasma samples from 66 melanoma patients using NeoGenomics' RaDaR® sequencing assay.

The study revealed that ctDNA detection post-surgery can identify patients with worse prognosis and enable earlier detection of disease recurrence. Notably, the research successfully identified ctDNA in patients lacking BRAF and NRAS mutations, suggesting broader applicability compared to earlier studies. The findings have led to the development of the CLEAR-Me trial for detecting and clearing MRD in high-risk melanoma patients.

NeoGenomics (NASDAQ: NEO) will present significant research on hematologic malignancies at the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego, December 7-10. The company will showcase findings on CNS lymphoma, myeloid malignancies, and gene fusions in acute myeloid leukemia.

The presentation includes a poster on neuronal-glial and immune microenvironment signatures in primary CNS lymphoma, scheduled for December 9. Additionally, two abstracts were published in the Blood supplement: one comparing genetic insights into myeloid malignancies across NCCN Guidelines, WHO Classification, and ICC System, and another studying gene fusion prevalence in 2,958 AML patients using FISH and NGS testing.

The company will also feature its hematological oncology solutions, including COMPASS, AML Express, and AML MRD Flow Panel at booth #2347.